



Health Services
LOS ANGELES COUNTY

January 15, 2008

**Los Angeles County
Board of Supervisors**

Gloria Molina
First District

Mark Ridley-Thomas
Second District

Zev Yaroslavsky
Third District

Don Knabe
Fourth District

Michael D. Antonovich
Fifth District

TO: Each Supervisor

FROM: John F. Schunhoff, Ph.D. 
Interim Director

SUBJECT: **NOTIFICATION OF EXERCISE OF DELEGATED
AUTHORITY TO EXTEND FIELD ADMINISTRATION
OF STROKE THERAPY- MAGNESIUM TRIAL STUDY
MEMORANDUM OF UNDERSTANDING NO. H-700794**

John F. Schunhoff, Ph.D.
Interim Director

Robert G. Splawn, M.D.
Interim Chief Medical Officer

313 N. Figueroa Street, Suite 912
Los Angeles, CA 90012

Tel: 213-240-8101
Fax: 213-481-0503

www.dhs.lacounty.gov

*To improve health
through leadership,
service and education*

This is to advise your Board that the Department of Health Services is exercising the delegated authority approved by your Board on June 19, 2007 (Attachment I), authorizing the Director of Health Services, or his designee, to amend the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Trial Study Memorandum of Understanding (MOU) with The Regents of the University of California on behalf of the University of California at Los Angeles (UCLA), contingent upon extension of the Department of Health and Human Services National Institutes of Health (NIH) Grant awarded to UCLA to fund the FAST-MAG Trial Study. A copy of the Notice of Grant Award for the period ending January 31, 2012, is attached (Attachment II).

This Amendment extends the MOU for 37 months, effective January 1, 2009 through January 31, 2012, based upon a revision to the FAST-MAG Grant Award issued by Department of Health and Human Services National Institutes of Health (NIH) whereby the project period was extended through January 31, 2012.

The CEO has reviewed and approved the Amendment (Attachment III). County Counsel has approved the Amendment as to form.

If you have any questions or require additional information, please let me know.

JFS:rg

Attachment

c: Chief Executive Officer
County Counsel
Executive Officer, Board of Supervisors

www.dhs.lacounty.gov





June 19, 2007

ADOPTED
BOARD OF SUPERVISORS
COUNTY OF LOS ANGELES

Los Angeles County
Board of Supervisors

Gloria Molina
First District

Yvonne B. Burke
Second District

Zev Yaroslavsky
Third District

Don Knabe
Fourth District

Michael D. Antonovich
Fifth District

The Honorable Board of Supervisors
County of Los Angeles
383 Kenneth Hahn Hall of Administration
500 West Temple Street
Los Angeles, California 90012

* 50

JUN 19 2007

Sachia Hamai
SACHIA HAMAI
EXECUTIVE OFFICER

Dear Supervisors:

**APPROVAL OF AMENDMENT NO. 1 TO THE FIELD
ADMINISTRATION OF STROKE THERAPY-MAGNESIUM TRIAL
STUDY MEMORANDUM OF UNDERSTANDING**
(All Districts) (3 Votes)

IT IS RECOMMENDED THAT YOUR BOARD:

1. Approve and instruct the Director of Health Services, or his designee, to execute Amendment No. 1 to the existing Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Trial Study Memorandum of Understanding (MOU), substantially similar to Exhibit I, with The Regents of the University of California on behalf of the University of California at Los Angeles (UCLA), to extend the current MOU term through December 31, 2007, with no net cost to the County.
2. Delegate authority to the Director of Health Services, or his designee, to sign any subsequent amendments to extend the FAST-MAG Trial Study MOU, on substantially similar terms, contingent upon extension of the Department of Health and Human Services National Institutes of Health (NIH) Grant awarded to UCLA, upon review and approval by County Counsel and the Chief Administrative Office, and notification to the Board.

Bruce A. Chernof, MD
Director and Chief Medical Officer

John R. Cochran III
Chief Deputy Director

Robert G. Splawt, MD
Senior Medical Director

313 N. Figueroa Street, Suite 912
Los Angeles, CA 90012

Tel: (213) 240-8101
Fax: (213) 481-0563

*To improve health
through leadership,
service and education.*

PURPOSE/JUSTIFICATION OF THE RECOMMENDED ACTIONS:

The purpose of the recommended actions is to obtain approval to execute an amendment to the existing FAST-MAG Trial Study MOU between UCLA and the Department of Health Services (DHS) Emergency Medical Services (EMS) Agency to extend the County's participation in the federally-funded FAST-MAG trial study whose primary objective is to determine if prehospital treatment with magnesium sulfate administered by paramedics in the field improves the long-term functional outcome of hyperacute stroke patients. The Amendment to the MOU also provides operational changes to allow the parties to modify the research protocol in accordance with Federal regulations and provide a more effective method to oversee the study.



www.ladhs.org

IMPLEMENTATION OF STRATEGIC PLAN GOALS:

These actions support the County's Strategic Plan Goal No. 1 for Service Excellence by enhancing the quality and availability of emergency medical care services countywide.

FISCAL IMPACT/FINANCING:

UCLA is the prime recipient of Grant No. 5 U01 NS044364-04 from the federal Department of Health and Human Services NIH (Attachment B) for the FAST-MAG trial study. DHS does not incur any costs associated with its continued participation in the FAST-MAG trial study.

FACTS AND PROVISIONS/LEGAL REQUIREMENTS:

On December 14, 2004, the Board approved an MOU with UCLA for participation of EMS in the FAST-MAG trial study. In accordance with California Code of Regulations, Title 22, Division 9, Section 100146, paramedics are authorized to perform any prehospital emergency medical care treatment procedure(s) or administer any medication(s) on a trial basis when approved by the medical director of the local EMS agency.

Under terms of the MOU, paramedics screen all prehospital emergency medical care patients for study entry. Inclusion and exclusion criteria for study participation has been established and included in the FAST-MAG Clinical Trial Protocol developed by UCLA. Inclusion of study participants is subject to the approval of an on-call FAST-MAG physician-investigator, and consent by the patient or his or her authorized representative. The FAST-MAG trial study was set up to fund up to 1,298 patients with acute stroke to be identified in the field by licensed paramedics in Los Angeles County. However, as of February 2007, only 300 subjects had enrolled in the study. Extending the current MOU term will ensure that all potential FAST-MAG trial study patients in Los Angeles County are identified, offered enrollment in the study, and have access to treatment that may improve their long-term functional outcome.

The FAST-MAG Trial Protocols for Enrollment and Consent have been revised to become effective with the proposed extension period. A new section, 3.1, Enrollment by Explicit Informed Consent, outlines requirements for the enrollment of study participants who are competent or who have an on-scene legally authorized representative. Another new section, 3.2, Enrollment in Emergency Circumstances of Non-competent Patients Without Written Informed Consent, outlines requirements for the enrollment of study participants who are non-competent patients without on-scene authorized representatives. The parties are obtaining final approvals as required by federal law for this trial study. To the extent the regulatory authorities require further additions, and to allow for more flexibility for the parties to design and conduct the study to best achieve its outcome, DHS will now be authorized under the Amendment to make further changes to the protocol upon approval by County Counsel.

The current federal NIH Grant for the FAST-MAG trial study expires December 31, 2007. A renewal of the Grant is expected to be awarded to UCLA for a four-year period, effective 2008 through 2012.

The Honorable Board of Supervisors
June 19, 2007
Page 3

Attachments A and B provide additional information.

County Counsel has approved Exhibit I as to use and form:

CONTRACTING PROCESS:


Not applicable.

IMPACT ON CURRENT SERVICES (OR PROJECTS):

Approval of this amendment and delegated authority to extend the MOU will enable DHS to continue participating in the FAST-MAG trial study to further evaluate the potential efficacy of intravenous magnesium sulfate administered by paramedics in the field to patients with acute stroke.

When approved, this Department requires three signed copies of the Board's action.

Respectfully submitted,



Bruce A. Chernof, M.D.
Director and Chief Medical Officer

BAC:cc
HWPBLETBL - FAST MAG.AE.wpd

Attachments (2)

c: Chief Administrative Officer
County Counsel
Executive Officer, Board of Supervisors
Auditor-Controller
Chair, Emergency Medical Services Commission
Health Care Association of Southern California
State Department of Health Services

SUMMARY OF MEMORANDUM OF UNDERSTANDING AMENDMENT

1. TYPE OF SERVICE

The Memorandum of Understanding (MOU) Amendment No.1 with The Regents of the University of California will extend the County's participation in the federally-funded Field Administration of Stroke Therapy-Magnesium (FAST-MAG) trial study through December 31, 2007.

2. AGENCY ADDRESS AND CONTACT PERSON

Sandra M. Perez
University of California at Los Angeles
Office of Contract and Grant Administration
FAST-MAG Clinical Trial Center
1072 Gayley Avenue
Los Angeles, California 90024-7325
Telephone: (310) 794-6155
E-mail: SMPerez@mednet.ucla.edu

3. TERM

The term of the MOU Amendment shall be effective July 1, 2007 through December 31, 2007.

4. FINANCIAL INFORMATION

The University of California at Los Angeles is the prime recipient of a grant from the federal Department of Health and Human Services National Institutes of Health for the FAST-MAG trial study. The Department of Health Services does not incur any additional costs associated with their continued participation in the FAST-MAG trial study.

5. PRIMARY GEOGRAPHIC AREA TO BE SERVED

Countywide.

6. APPROVALS

Emergency Medical Services:	Cathy Chidester, Acting Director
Contracts and Grants Division:	Cara O'Neill, Chief
County Counsel:	Edward A. Morrissey, Senior Deputy County Counsel
CAO Budget Unit:	Latisha Thompson

NOTICE OF GRANT AWARD

RESEARCH PROJECT COOPERATIVE AGREEMENT

Issue Date: 03/27/2007

Department of Health and Human Services
National Institutes of Health

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

Grant Number: 5 U01 NS044364-04
Principal Investigator: SAVER, JEFFREY L MD
Project Title: Field Administration of Stroke Therapy - Magnesium Trial

GRANT ANALYST
UNIV OF CALIFORNIA
OFC OF CONTRACT/ GRANT ADMIN
10920 WILSHIRE BLVD, STE 1200
LOS ANGELES, CA 900241406
UNITED STATES
Award e-mailed to: NIHAward@resadmin.ucla.edu

Budget Period: 01/01/2007 - 12/31/2007
Project Period: 09/30/2003 - 12/31/2007

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$1,000,000 (see "Award Calculation" in Section D) to UNIVERSITY OF CALIFORNIA LOS ANGELES in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to terms and conditions referenced below. Acceptance of this award including the Terms and Conditions is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Award recipients are responsible for reporting inventions derived or reduced to practice in the performance of work under this grant. Rights to inventions vest with the grantee organization provided certain requirements are met and there is acknowledgement of NIH support. In addition, recipients must ensure that patent and license activities are consistent with their responsibility to make unique research resources developed under this award available to the scientific community, in accordance with NIH policy. For additional information, please visit <http://www.iedison.gov>.

If you have any questions about this award, please contact the individual(s) referenced in the information below.

Sincerely yours,

King P. Bond, Jr.



Grant Number: 2U01NS044364-05 REVISED

Principal Investigator(s):
JEFFREY L SAVER, MD

Project Title: Field Administration of Stroke Therapy-Magnesium Trial (FAST-MAG)

SENIOR GRANT ANALYST
UNIV OF CALIFORNIA, LOS ANGELES
OFC OF CONTRACT & GRANT ADMIN
10920 WILSHIRE BLVD, SUITE 1200
LOS ANGELES, CA 90024-1406

Award e-mailed to: NIHAward@research.ucla.edu

Budget Period: 06/01/2008 – 01/31/2009
Project Period: 07/01/2002 – 01/31/2012

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF CALIFORNIA LOS ANGELES in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number U01NS044364 from the National Institute Of Neurological Disorders And Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Neurological Disorders And Stroke or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

James Washington
Grants Management Officer
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

Additional information follows

SECTION I – AWARD DATA – 2U01NS044364-05 REVISED

Award Calculation (U.S. Dollars)

Salaries and Wages	\$2,408,058
Fringe Benefits	\$644,399
Personnel Costs (Subtotal)	\$3,052,457
Consultant Services	\$600
Equipment	\$19,479
Supplies	\$21,000
Travel Costs	\$40,000
Other Costs	\$274,011
Consortium/Contractual Cost	\$567,174

Federal Direct Costs	\$3,974,721
Federal F&A Costs	\$918,554
Approved Budget	\$4,893,275
Federal Share	\$4,893,275
TOTAL FEDERAL AWARD AMOUNT	\$4,893,275

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
5	\$4,893,275	\$4,893,275
6	\$4,967,482	\$4,967,482
7	\$5,098,544	\$5,098,544
8	\$3,336,801	\$3,336,801

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.853
 EIN: 1956006143A1
 Document Number: UNS044364B
 Fiscal Year: 2008

IC	CAN	2008	2009	2010	2011
NS	8472428	\$4,893,275	\$4,967,482	\$5,098,544	\$3,336,801

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: JANISSCT / OC: 414M / Processed: WASHINGTON 07/02/2008

SECTION II – PAYMENT/HOTLINE INFORMATION – 2U01NS044364-05 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 2U01NS044364-05 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase IV Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

**Treatment of Program Income:
Additional Costs**

SECTION IV – NS Special Terms and Conditions – 2U01NS044364-05 REVISED

This revision changes the budget period and project period end dates. The -05 budget period has been shortened and is now scheduled to end on 01/31/2009. All future budget periods will have an anniversary date of February 1st.

THE PREVIOUS TERMS AND CONDITIONS STATED BELOW REMAIN IN EFFECT.

Funds included in this award may not be used to support studies involving human subjects until certification of the IRB approval for the performance sites listed below has been submitted to and approved by NINDS. See Office of Human Research Protection (OHRP) Web site: <http://ohrp.osophis.dhhs.gov/index.htm>.

Only activities which do not directly involve human subjects (i.e., are clearly severable and independent from those activities that do involve human subjects) may be conducted until the IRB certification has been provided to the NINDS. No funds may be drawn down from the payment system and no obligations may be made against federal funds for any research involving human subjects in this project at the sites listed below pending NINDS receipt and acceptance of the certification of IRB approval.

Sites restricted pending IRB approval:

- | | |
|--|---|
| 1. Antelope Valley Hospital | 2. Henry Mayo Newhall Memorial Hospital |
| 3. Huntington Memorial Hospital | 4. Little Company of Mary-San Pedro |
| 5. Little Company of Mary - Torrance | 6. Long Beach Memorial Medical Center |
| 7. Methodist Hospital of Southern California | 8. Northridge Hospital Medical Center |
| 9. St. Mary Medical Center | 10. Providence Holy Cross Foundation |
| 11. Providence Saint Joseph Medical Ctr. | 12. California Hospital Medical Ctr. |
| 13. Verdugo Hills Hospital | 14. Glendale Adventist |
| 15. Kaiser Foundation Hospitals-Woodland Hills | 16. Mission Community |
| 17. Olive View/UCLA EDU. & Research Institute | 18. St. Francis Med. Ctr. Mission Cmnty |
| Hospital- Panorama | |
| 19. St. John's Hlth Ctr. | 20. Kaiser Foundation Hospitals - South Bay |
| 21. Kaiser Foundation Hospitals-Panorama City | 22. Brotman Medical Ctr. |
| 23. Kaiser Foundation Hospitals-Sunset | |
| 24. Kaiser Foundation Hospitals-West La | 25. Kaiser Foundation Hospitals-Bellflower |
| 26. Cedars-Sinai Medical Ctr. | 27. Centinela Hospital Medical Ctr. |
| 28. Centinela Freeman Regional Med. Ctr-Marina | 29. Century City Doctors Hospital |
| 30. Citrus Valley Med. Ctr.-Inter-Community Campus | 31. Citrus Valley Medi. Ctr.-Quern of the |
| Valley Campus | |
| 32. Encino-Tarzana Regional Med. Ctr | 33. Glendale Memorial Hospital |
| 34. Good Samaritan Hospital | 35. Olympia Med. Ctr. |
| 36. Pomona Valley Hospital | 37. San Dimas Community Hospital |
| 38. Sherman Oaks Hospital | 39. West Hills Hospital & Med. Ctr. |
| 40. White Memorial Med. Ctr. | 41. Whittier Hospital Med. Ctr. |
| 42. Torrance Memorial Med. Ctr. | 43. Lakewood Regional Med. Ctr. |
| 44. Presbyterian Intercommunity | 45. Valley Presbyterian Hospital |

Individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Aricia M. Ajose
Email: ajosea@ninds.nih.gov **Phone:** 301-496-8072 **Fax:** 301-451-5635

Program Official: Scott Janis
Email: janiss@ninds.nih.gov **Phone:** (301) 496-9135 **Fax:** (301) 480-1080

SPREADSHEET SUMMARY

GRANT NUMBER: 2U01NS044364-05 REVISED

INSTITUTION: UNIVERSITY OF CALIFORNIA LOS ANGELES

Budget	Year 5	Year 6	Year 7	Year 8
Salaries and Wages	\$2,408,058	\$2,473,129	\$2,540,148	\$1,556,343
Fringe Benefits	\$644,399	\$662,238	\$680,614	\$416,131
Personnel Costs (Subtotal)	\$3,052,457	\$3,135,367	\$3,220,762	\$1,972,474
Consultant Services	\$600	\$618	\$637	\$656
Equipment	\$19,479			
Supplies	\$21,000	\$21,000	\$21,000	\$13,000
Travel Costs	\$40,000	\$40,000	\$40,000	\$25,000
Other Costs	\$274,011	\$282,865	\$292,412	\$187,244
Consortium/Contractual Cost	\$567,174	\$581,528	\$594,282	\$566,850
TOTAL FEDERAL DC	\$3,974,721	\$4,061,378	\$4,169,093	\$2,765,224
TOTAL FEDERAL F&A	\$918,554	\$906,104	\$929,451	\$571,577
TOTAL COST	\$4,893,275	\$4,967,482	\$5,098,544	\$3,336,801

Facilities and Administrative Costs	Year 5	Year 6	Year 7	Year 8
F&A Cost Rate 1	26%	26%	26%	26%
F&A Cost Base 1	\$3,532,901	\$3,485,017	\$3,574,811	\$2,198,374
F&A Costs 1	\$918,554	\$906,104	\$929,451	\$571,577

Contract # _____

**FIELD ADMINISTRATION OF STROKE THERAPY-MAGNESIUM TRIAL STUDY
MEMORANDUM OF UNDERSTANDING**

AMENDMENT NO. 3

THIS AMENDMENT is made and entered into this _____ day
of _____, 2009,

by and between

COUNTY OF LOS ANGELES
(hereafter "County"),

and

THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA
(hereafter "Contractor").

WHEREAS, reference is made to that certain document entitled
"FIELD ADMINISTRATION OF STROKE THERAPY-MAGNESIUM TRIAL STUDY
MEMORANDUM OF UNDERSTANDING", dated December 14, 2004, and
further identified as County Memorandum of Understanding No.
H-700794 (hereafter referred to as "MOU"); and

WHEREAS, the parties wish to extend the MOU's term for an
additional thirty-seven (37) months, to and including January 31,
2012, subject to the right of either party to terminate and
withdraw from the relationship prior to that date, with or
without cause, by giving at least sixty (60) calendar days prior
written notice thereof to the other party; and

WHEREAS, MOU provides that changes may be made in the form of a written amendment which is formally approved and executed by the parties.

NOW, THEREFORE, the parties agree as follows:

1. Paragraph 2, TERM, of MOU shall be deleted in its entirety and replaced with the following:

"This MOU shall commence effective December 14, 2004, and it shall continue in full force and effect to and including January 31, 2012."

2. Subparagraph "A" of Paragraph 4, COOPERATION AND COMPLIANCE, of MOU shall be revised to read as follows:

"A. The EMS Agency and UCLA agree to cooperate with each other for the purpose of conducting the FAST-MAG Trial study in order to meet the requirements outlined under original granting agency in accordance with Grant Number 1 U01 NS044364, Grant Number 5 U01 NS044364-04, and Grant Number 2 U01 NS044364-05."

3. Paragraph 6, INCORPORATION BY REFERENCE, of MOU shall be revised to read as follows:

"6. The terms and conditions of the grant program legislation and regulations under which the prime grant award was made, the prime grant Notice of Grant Award ("NGA") including all its special terms and conditions, 45

CFR Part 74, are made a part hereof by reference. A copy of the NGA for the period ending January 31, 2012, is attached as Attachment II."

4. Except for the changes set forth hereinabove, the wording of MOU shall not be changed in any respect by this Amendment.

IN WITNESS WHEREOF, the Board of Supervisors of the County of Los Angeles has caused this MOU to be subscribed by its

/

/

/

/

/

/

/

/

/

/

/

/

/

/

/

/

Director of Health Services and Contractor has caused this MOU to be subscribed in its behalf by its duly authorized officer, the day, month, and year first above written.

COUNTY OF LOS ANGELES

By

John F. Schunhoff, Ph.D.
Interim Director

THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA
Contractor

By

Signature

Printed Name

Title

(AFFIX CORPORATE SEAL HERE)

APPROVED AS TO FORM:
OFFICE OF THE COUNTY COUNSEL

APPROVED AS TO CONTRACT
ADMINISTRATION:

DEPARTMENT OF HEALTH SERVICES
CONTRACTS AND GRANTS DIVISION